Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > NASDAQ

<< Previous

Bullboard Posts

Next >>

Comment by Doccoleon Mar 23, 2021 12:20pm

191 Views

Post# 32858457

RE:NASDAQ

Really a good question or will they be taken out before uplist?

I can't wait to see why Dano is dragging his feet on this? His initial lie was about getting word out. Well he allegedly did that with Sterns. The second tease was a beginning of the year uplist.....we have wind in our sail with money, proof of concept and now a all star group I call my dinner party. We shall see!

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China